Article citationsMore>>
Peters, S, Spigel, D., Ahn, M., Tsuboi, M., Chaft, J., Harpole, D., Goss, G., Arlesi, F.B., Abbosh, C., Polle, L., May, R., Dennis, P.A. and Swanton, C. (2021) P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery. Journal of Thoracic Oncology, 16, S258-S259.
https://doi.org/10.1016/j.jtho.2021.01.376
has been cited by the following article:
-
TITLE:
Immunotherapy in Early Stage Non-Small Cell Lung Cancer
AUTHORS:
Jeyanthi Ramanarayanan, Ganapathy Krishnan
KEYWORDS:
Non-Small Cell Lung Cancer, Immunotherapy, Immune Checkpoint Inhibitors, Adjuvant, Neoadjuvant, Early Stage
JOURNAL NAME:
Advances in Lung Cancer,
Vol.11 No.3,
September
1,
2022
ABSTRACT: Immune-checkpoint inhibitors are extensively used in
cancer treatment and have transformed the therapeutic landscape by inducing
durable responses. Immunotherapy with checkpoint inhibitors targeting
programmed death 1 (PD-1) receptor and programmed death ligand-1 (PDL-1) are
used alone or with chemotherapy for treatment of metastatic non-small cell lung
cancer (NSCLC). There is a great need for improving outcomes of patients with
early stage NSCLC after surgical resection and with recent F. D. A. approval, immune checkpoint inhibitors are
used as neoadjuvant or adjuvant therapy to enable curative resection and
prevent or delay disease progression. In this article, we review the clinical studies evaluating the role of adjuvant
and neoadjuvant immune checkpoint inhibitors in NSCLC and discuss the
role of immunotherapy with radiation therapy in locally advanced non-metastatic
NSCLC.
Related Articles:
-
Takanori Ayabe, Masaki Tomita, Kunihide Nakamura
-
Shuichi Tsukamoto, Koji Yamazaki, Ryo Mori, Masakazu Katsura, Hidenori Kouso, Daigo Kawano, Chie Ushijima, Sadanori Takeo
-
Jai Dev Chandel, Nand Lal Singh
-
Tiama Guy Nicaise Ballet, Kôkôh Rose Effebi, Olga Yolande Aké Ako, Yapo Habib Kpidi, Ossey Bernard Yapo
-
Sarah Tasneem, Lester Lipsky, Reda Ammar, Howard Sholl